Low
₹
High
₹
| Previous Close | ₹32.24 |
|---|---|
| Day's Range | ₹32.00 - ₹33.84 |
| Open | ₹33.60 |
| 52 Week Range | ₹25.60 - ₹66.00 |
| Volume | 3,197 |
| Market Cap | ₹0.00 |
| Trade Value ( ₹ in Lacs) | 1.05 |
|---|---|
| Market Cap (₹ in Mn) | 0.00 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 0.00 |
| TTM EPS (₹) | -1.29 |
| P/E Ratio | 0.00 |
| Book Value(₹) | 2.30 |
| PAT Margin (%) | -69.44 |
| Face Value (₹) | 10.00 |
| ROCE(%) | -17.65 |
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 11.15 | 23.41 |
| Expenses | N/A | N/A |
| PBT | -56.92 | -85.87 |
| Operating profit | 0.0 | 0.0 |
| Net profit | -43.63 | -72.79 |
| Founded | 1989 |
|---|
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,56,089.58 | 1,900.90 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 2,26,975.64 | 8,550.00 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,85,638.53 | 4,880.50 | 3,480.60 - 3,480.60 |
| Apollo Hospitals Enterprise Ltd. | 1,24,503.13 | 8,659.00 | 6,696.50 - 6,696.50 |
| Cipla Ltd. | 1,15,216.02 | 1,426.20 | 1,165.70 - 1,165.70 |
| Lenskart Solutions Ltd. | 1,15,063.80 | 661.55 | 0.00 - 0.00 |
| Zydus Lifesciences Ltd. | 1,11,720.43 | 1,120.00 | 835.50 - 835.50 |
| Lupin Ltd. | 1,00,271.61 | 2,193.00 | 1,875.00 - 1,875.00 |
| Dr. Reddy's Laboratories Ltd. | 98,074.41 | 1,175.00 | 1,101.00 - 1,101.00 |
| Laurus Labs Ltd. | 98,047.76 | 1,814.65 | 823.10 - 823.10 |
No Records Found
Pursuant to Regulation 30 and 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Pharmaids Pharmaceuticals has informed that it enclosed copies of the newspaper advertisement pertaining to the unaudited financial results of the company for the quarter ended June 30, 2026. The advertisement was published on Friday, August 14, 2026, in English Newspaper having nationwide circulation 'Financial Express' and Vernacular Newspaper 'Hosa Digantha'. This information will also be made available on the Company’s website at: www.pharmaids.com.
The above information is a part of company’s filings submitted to BSE.
Pursuant Regulation 30 read with Schedule III of Listing Regulations, Pharmaids Pharmaceuticals has informed that the Board of Directors of the Company at their meeting held on Tuesday, June 30, 2026, have, basis recommendation of the Audit Committee, considered and approved the appointment of V Mahendra & Associates Chartered Accountants (FRN: 025356S) as Internal Auditors of the Company for carrying out the Internal Audit for the financial year 2026-27. The disclosure as required under Regulation 30 of the Listing Regulations read with SEBI Master Circular dated January 30, 2026, is enclosed as Annexure A. The above Information is being made available on the Company’s website: www.pharmaids.com.
The above information is a part of company’s filings submitted to BSE.
Vijaya Diagnostic Centre has informed about Cessation of Dr. Manjula Anagani as Independent Director on completion of tenure w.e.f 21.08.2026.
The above information is a part of company's filings submitted to BSE.
No Records Found
The current share price of Pharmaids Pharmaceuticals Ltd. is ₹32.24 as of 2026-08-21.
The market capitalisation of Pharmaids Pharmaceuticals Ltd. is ₹113.70 as of 2026-08-21.
The 1-year return of Pharmaids Pharmaceuticals Ltd. is -29.76% as of 2026-08-21.
The P/E ratio of Pharmaids Pharmaceuticals Ltd. is 0.00 as of 2026-08-23.
The 52-week high and low of Pharmaids Pharmaceuticals Ltd. are ₹66.00 and ₹25.60, respectively, as of 2026-08-21.
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.